StockTipsArenaBeta

BUY Supriya Lifescience Limited — Madhu Bansal

BUYSupriya Lifescience Limited
Supriya Lifescience share price target & all analyst calls

byMadhu BansalHorizon: NA (inferred Swing (≤2wk))11 Nov 2026via CNBC Awaaz.

Entry₹657.9Inferred
Target₹725
Total upside +10.20% (call closed)
Stop loss₹640-2.72% risk
Exit₹64011 Nov 2026, 2:00 pm
Stop-loss hit-2.72%
Follow Madhu Bansal for new calls(25% target hit, 56 closed calls)Get alertsWatch SUPRIYA for new buy/sell callsGet alertsSee 282 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 11 Nov 2026
0 supporting1 neutral2 opposing
Supports the BUY call (0)

Nothing found in this tip’s window yet.

Neutral / worth noting (1)

Supriya Lifescience reported unaudited financial results for the quarter and half year ended September 30, 2026, and announced the appointment of Mr. Mangesh Vaze as Chief Operating Officer.

BSE · Board Meeting·6 Nov · 5d ago

(opens in new tab)
Weighs against the BUY call (2)

Supriya Lifescience reported Q2 FY27 PAT of Rs 29.25 crore, down from Rs 50.43 crore in Q2 FY26, with EBITDA margins contracting to 22.0% from 36.4% due to regulatory changes and higher operating cost

BSE · Company Update·6 Nov · 4d ago

(opens in new tab)

Supriya Lifescience reported Q2 FY27 revenue of Rs 206.30 crore, up 3.2% YoY, but EBITDA fell to Rs 45.40 crore from Rs 72.65 crore and PAT dropped to Rs 29.25 crore from Rs 50.43 crore.

NSE · Press Release·6 Nov · 4d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Supriya Lifescience

All analyst calls on Supriya Lifescience

More from Madhu Bansal

Every call and its outcome